Q1 2025 Medpace Holdings Inc Earnings Call Transcript
Key Points
- Revenue for the first quarter of 2025 was $558.6 million, representing a year-over-year increase of 9.3%.
- Net income for the first quarter increased by 11.7% compared to the prior year, reaching $114.6 million.
- Medpace Holdings Inc (MEDP) generated $125.8 million in cash flow from operating activities during the first quarter.
- The company repurchased approximately 1.19 million shares for $389.8 million, indicating strong capital return to shareholders.
- Guidance for full-year 2025 revenue is expected to be in the range of $2.14 billion to $2.24 billion, showing potential growth over 2024.
- Net new business awards entering backlog in the first quarter decreased by 18.8% from the prior year.
- The net book-to-bill ratio was 0.90, indicating a decline in new business relative to revenue.
- Backlog cancellations were modestly elevated, with pre-backlog cancellations being significantly worse.
- EBITDA margin for the first quarter was 21.2%, down from 22.6% in the prior year period.
- The company faces increased price competition and variability in the quality of RFPs, impacting business decisions.
Good day ladies and gentlemen, and welcome to the Medpace first quarter 2025 earnings conference call. (Operator Instructions) As a reminder, this call is being recorded.
I would now like to introduce your host for today's conference call, Lauren Morris, Medpace's Director of Investor Relations. You may begin.
Good morning and thank you for joining Medpace's first quarter 2025 earnings conference call. Also on the call today is our CEO, August Troendle; our President, Jesse Geiger; and our CFO, Kevin Brady. Before we begin, I would like to remind you that our remarks and responses to your questions during this teleconference may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
These statements involve inherent assumptions with known and unknown risks and uncertainties, as well as other important factors that could cause actual results to differ materially from our current expectations. These factors are discussed
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
